shah faisal mbbs mentor joseph a. caruana md. aim and objective
TRANSCRIPT
Shah Faisal MBBS
Mentor
Joseph A. Caruana MD
Aim and Objective
Aim and ObjectiveSome patients after Roux-en-Y Gastric Bypass undergo
“Sub-optimal” Weight Loss (SWL).
Aim and ObjectiveSome patients after Roux-en-Y Gastric Bypass undergo
“Sub-optimal” Weight Loss (SWL).Age, Gender and BMI are the major contributors to
weight loss pattern.
Aim and ObjectiveSome patients after Roux-en-Y Gastric Bypass undergo
“Sub-optimal” Weight Loss (SWL).Age, Gender and BMI are the major contributors to
weight loss pattern.Are there any more subtle and/or modifiable variables
which play a role?
Problem of Obesity
Problem of Obesity Two thirds of individuals living in the US are
overweight, and of those, almost half are obese.
Problem of Obesity Two thirds of individuals living in the US are
overweight, and of those, almost half are obese. DM-2, dyslipidemia, CAD, HTN, OSA are a few of the
myriad complications that obesity predisposes to.
Problem of Obesity Two thirds of individuals living in the US are
overweight, and of those, almost half are obese. DM-2, dyslipidemia, CAD, HTN, OSA are a few of the
myriad complications that obesity predisposes to. Known association with some common cancers:
Problem of Obesity Two thirds of individuals living in the US are
overweight, and of those, almost half are obese. DM-2, dyslipidemia, CAD, HTN, OSA are a few of the
myriad complications that obesity predisposes to. Known association with some common cancers:
Liver, kidney, breast, endometrial, prostate, colon…
Problem of Obesity Two thirds of individuals living in the US are
overweight, and of those, almost half are obese. DM-2, dyslipidemia, CAD, HTN, OSA are a few of the
myriad complications that obesity predisposes to. Known association with some common cancers:
Liver, kidney, breast, endometrial, prostate, colon…Huge burden on healthcare cost:
Problem of Obesity Two thirds of individuals living in the US are
overweight, and of those, almost half are obese. DM-2, dyslipidemia, CAD, HTN, OSA are a few of the
myriad complications that obesity predisposes to. Known association with some common cancers:
Liver, kidney, breast, endometrial, prostate, colon…Huge burden on healthcare cost:
25 % greater among subjects with a BMI 30 to 34.9
Problem of Obesity Two thirds of individuals living in the US are
overweight, and of those, almost half are obese. DM-2, dyslipidemia, CAD, HTN, OSA are a few of the
myriad complications that obesity predisposes to. Known association with some common cancers.
Liver, kidney, breast, endometrial, prostate, colon…Huge burden on healthcare cost:
25 % greater among subjects with a BMI 30 to 34.944 % greater among those with a BMI > 35
Treatment
TreatmentMedical treatment:
TreatmentMedical treatment:
Diet, exercise and life style modification.
TreatmentMedical treatment:
Diet, exercise and life style modification.Medications.
TreatmentMedical treatment:
Diet, exercise and life style modification.Medications.
Surgical treatment:
TreatmentMedical treatment:
Diet, exercise and life style modification.Medications.
Surgical treatment:Roux-en-Y Gastric By-pass.
TreatmentMedical treatment:
Diet, exercise and life style modification.Medications.
Surgical treatment:Roux-en-Y Gastric By-pass.Adjustable Gastric Banding.
TreatmentMedical treatment:
Diet, exercise and life style modification.Medications.
Surgical treatment:Roux-en-Y Gastric By-pass.Adjustable Gastric Banding.Diet, exercise and life style modification are part of surgical
treatment.
Dietary and Exercise recommendation after Gastric Bypass
Dietary and Exercise recommendation after Gastric BypassDiet:
1200-1400 Cal per day.60-80 g protein per day.4-5 small meals (especially breakfast).32 oz water per day.
Dietary and Exercise recommendation after Gastric BypassDiet:
1200-1400 Cal per day.60-80 g protein per day.4-5 small meals (especially breakfast).32 oz water per day.
Exercise:Walking 30 min/day, five to seven days per week.
Roux en Y Gastric By-pass
Adjustable Gastric band
Weight Loss after Gastric Bypass
Weight Loss after Gastric BypassHow do Age, Gender and BMI influence weight loss?
Weight Loss after Gastric BypassHow do Age, Gender and BMI influence weight loss?Recent work done by Dr Caruana:
Weight Loss after Gastric BypassHow do Age, Gender and BMI influence weight loss?Recent work done by Dr Caruana:
Weight Loss Curves.
Weight Loss after Gastric BypassHow do Age, Gender and BMI influence weight loss?Recent work done by Dr Caruana:
Weight Loss Curves.Effect of Age, Gender and BMI on weight loss.
959075
50
25 10 5
9590755025 10 5
Red Lines >41 yrBlack Lines <41 yr
Red Lines FemalesBlack Lines Males
9590755025 10 5
Red Lines BMI>55Black Lines BMI<55
9590755025 10 5
Sub-Optimal Weight Loss (SWL)
Sub-Optimal Weight Loss (SWL)SWL < 40% (to 50%) Excess Body Weight (EBW) lost.
Sub-Optimal Weight Loss (SWL)SWL < 40% (to 50%) Excess Body Weight (EBW) lost.EBW is actual weight minus Ideal Body Weight (IBW).
Sub-Optimal Weight Loss (SWL)SWL < 40% (to 50%) Excess Body Weight (EBW) lost.EBW is actual weight minus Ideal Body Weight (IBW).IBW from 1983 Metropolitan Height and Weight Tables.
Sub-Optimal Weight Loss (SWL)SWL < 40% (to 50%) Excess Body Weight (EBW) lost.EBW is actual weight minus Ideal Body Weight (IBW).IBW from 1983 Metropolitan Height and Weight Tables.Around 10% (to 20%) of Gastric Bypass patients have
SWL:
Sub-Optimal Weight Loss (SWL)SWL < 40% (to 50%) Excess Body Weight (EBW) lost.EBW is actual weight minus Ideal Body Weight (IBW).IBW from 1983 Metropolitan Height and Weight Tables.Around 10% (to 20%) of Gastric Bypass patients have
SWL:Most of the patients actually regain the weight.
Methods
MethodsMatched Case-Control Study.
MethodsMatched Case-Control Study.Controls matched to cases for Age, Gender & BMI.
MethodsMatched Case-Control Study.Controls matched to cases for Age, Gender & BMI. Four matched controls for every case.
Inclusion/Exclusion Criteria
Inclusion/Exclusion CriteriaGastric bypass between Jan ’00 and Dec ‘07.
Inclusion/Exclusion CriteriaGastric bypass between Jan ’00 and Dec ‘07. Followed up at 18 (±2) months after surgery.
Inclusion/Exclusion CriteriaGastric bypass between Jan ’00 and Dec ‘07. Followed up at 18 (±2) months after surgery. At 18 (± 2) months:
Inclusion/Exclusion CriteriaGastric bypass between Jan ’00 and Dec ‘07. Followed up at 18 (±2) months after surgery. At 18 (± 2) months:
If lost < 40% EBW—Case.
Inclusion/Exclusion CriteriaGastric bypass between Jan ’00 and Dec ‘07. Followed up at 18 (±2) months after surgery. At 18 (± 2) months:
If lost < 40% EBW—Case. If lost >40% EBW—Potential Control.
Cases Controls
Break Down of Cases & Controls
Cases Controls
Number 21 84
Break Down of Cases & Controls
Cases Controls
Number 21 84
Gender
FemalesMales
201
804
Break Down of Cases & Controls
Cases Controls
Number 21 84
Gender
FemalesMales
201
804
Age (Years) MeanRange
4535
4538
Break Down of Cases & Controls
Cases Controls
Number 21 84
Gender
FemalesMales
201
804
Age (Years) MeanRange
4535
4538
BMI MeanRange
5537
5540
Break Down of Cases & Controls
Cases Controls
Number 21 84
Gender
FemalesMales
201
804
Age (Years) MeanRange
4535
4538
BMI MeanRange
5537
5540
Working (%) YesNo
6040
6436
Break Down of Cases & Controls
Cases Controls
Number 21 84
Gender
FemalesMales
201
804
Age (Years) MeanRange
4535
4538
BMI MeanRange
5537
5540
Working (%) YesNo
6040
6436
Smoking (%) YesNo
1090
1783
Break Down of Cases & Controls
Cases Controls
Number 21 84
Gender
FemalesMales
201
804
Age (Years) MeanRange
4535
4538
BMI MeanRange
5537
5540
Working (%) YesNo
6040
6436
Smoking (%) YesNo
1090
1783
Race (%) WhiteBlack
9010
8317
Break Down of Cases & Controls
Data CollectionRetrospective Chart Review.
Data CollectionRetrospective Chart Review.Variables:
Data CollectionRetrospective Chart Review.Variables:
DemographicAnthropometricSocialComplianceDisease CharacteristicsCo-morbiditiesRelated DiseasesPeri-operative
Type of Variable
Variables
Demographic Race, (Age and Gender Matched)
Type of Variable
Variables
Demographic Race, (Age and Gender Matched)
Anthropometric (BMI Matched)
Type of Variable
Variables
Demographic Race, (Age and Gender Matched)
Anthropometric (BMI Matched)
Social Work StatusSmoking Status
Type of Variable
Variables
Demographic Race, (Age and Gender Matched)
Anthropometric (BMI Matched)
Social Work StatusSmoking Status
Compliance Total Number of Follow-up VisitsDietary Compliance at Follow-upExercise Compliance at Follow-up
Type of Variable
Variables
Demographic Race, (Age and Gender Matched)
Anthropometric (BMI Matched)
Social Work StatusSmoking Status
Compliance Total Number of Follow-up VisitsDietary Compliance at Follow-upExercise Compliance at Follow-up
Disease Characteristics
Duration of ObesityFamily H/O Obesity
Type of Variable
Variables
Demographic Race, (Age and Gender Matched)
Anthropometric (BMI Matched)
Social Work StatusSmoking Status
Compliance Total Number of Follow-up VisitsDietary Compliance at Follow-upExercise Compliance at Follow-up
Disease Characteristics
Duration of ObesityFamily H/O Obesity
Co-morbidities No. of Co-morbidities (DM, HTN, Dyslipidemia, OSA, Arthritis, and GERD)Hepatic SteatosisNo. of Prescription MedicationsSeverity of DM, HTN and Dyslipidemia
Type of Variable
Variables
Demographic Race, (Age and Gender Matched)
Anthropometric (BMI Matched)
Social Work StatusSmoking Status
Compliance Total Number of Follow-up VisitsDietary Compliance at Follow-upExercise Compliance at Follow-up
Disease Characteristics
Duration of ObesityFamily H/O Obesity
Co-morbidities No. of Co-morbidities (DM, HTN, Dyslipidemia, OSA, Arthritis, and GERD)Hepatic SteatosisNo. of Prescription MedicationsSeverity of DM, HTN and Dyslipidemia
Related Diseases DepressionThyroid DysfunctionH/O Major Surgeries
Type of Variable
Variables
Demographic Race, (Age and Gender Matched)
Anthropometric (BMI Matched)
Social Work StatusSmoking Status
Compliance Total Number of Follow-up VisitsDietary Compliance at Follow-upExercise Compliance at Follow-up
Disease Characteristics
Duration of ObesityFamily H/O Obesity
Co-morbidities No. of Co-morbidities (DM, HTN, Dyslipidemia, OSA, Arthritis, and GERD)Hepatic SteatosisNo. of Prescription MedicationsSeverity of DM, HTN and Dyslipidemia
Related Diseases DepressionThyroid DysfunctionH/O Major Surgeries
Peri-operative Cholecystectomy done at ORPost-op LeakPost-op PEReturn to OR in 30 days
Statistical Analysis
Statistical AnalysisBinary predictors between the case and control group—
the exact Cochran-Mantel-Haenszel test:
Statistical AnalysisBinary predictors between the case and control group—
the exact Cochran-Mantel-Haenszel test:Common odds ratio with a corresponding exact 95%
confidence interval was estimated.
Statistical AnalysisBinary predictors between the case and control group—
the exact Cochran-Mantel-Haenszel test:Common odds ratio with a corresponding exact 95%
confidence interval was estimated.Mixed linear—Between-group Mean Difference.
Statistical AnalysisBinary predictors between the case and control group—
the exact Cochran-Mantel-Haenszel test:Common odds ratio with a corresponding exact 95%
confidence interval was estimated.Mixed linear—Between-group Mean Difference. A nominal significance level of 0.05 was used.
Statistical AnalysisBinary predictors between the case and control group—
the exact Cochran-Mantel-Haenszel test:Common odds ratio with a corresponding exact 95%
confidence interval was estimated.Mixed linear—Between-group Mean Difference. A nominal significance level of 0.05 was used.A multivariate model was constructed using a stepwise
conditional logistic regression procedure.
Statistical AnalysisBinary predictors between the case and control group—
the exact Cochran-Mantel-Haenszel test:Common odds ratio with a corresponding exact 95%
confidence interval was estimated.Mixed linear—Between-group Mean Difference. A nominal significance level of 0.05 was used.A multivariate model was constructed using a stepwise
conditional logistic regression procedure.SAS version 9.1.3 statistical software (Cary, NC).
Variable OR 95% CI p- Value
Diabetes Y vs. N 0.6 (0.1931, 2.4302) 0.567
Binary Predictors—the exact Cochran-Mantel-Haenszel test
Variable OR 95% CI p- Value
Diabetes Y vs. N 0.6 (0.1931, 2.4302) 0.567
Binary Predictors—the exact Cochran-Mantel-Haenszel test
Binary Predictor—Yes or No
Variable OR 95% CI p- Value
Diabetes Y vs. N 0.6 (0.1931, 2.4302) 0.567
Binary Predictors—the exact Cochran-Mantel-Haenszel test
Binary Predictor—Yes or No
Odds of normal weight loss if DM =0.6Odds of normal weight loss if not DM
Variable OR 95% CI p- Value
Diabetes Y vs. N 0.6 (0.1931, 2.4302) 0.567
Binary Predictors—the exact Cochran-Mantel-Haenszel test
Binary Predictor—Yes or No
Odds of normal weight loss if DM =0.6Odds of normal weight loss if not DM
95% Confidence that OR lies between (0.1931, 2.4302)
Variable OR 95% CI p- Value
Diabetes Y vs. N 0.6 (0.1931, 2.4302) 0.567
Binary Predictors—the exact Cochran-Mantel-Haenszel test
Binary Predictor—Yes or No
Odds of normal weight loss if DM =0.6Odds of normal weight loss if not DM
95% Confidence that OR lies between (0.1931, 2.4302)
P-Value < 0.05 for a relationship to be statistically significant, otherwise could be just by chance
Variable Estimated Mean Difference(Control—Case)
95% CI p- Value
No. of Medications @ follow-up -1.4 (0.5079, 2.4206) 0.0031
Mixed Linear Models—Between-group mean difference
Variable Estimated Mean Difference(Control—Case)
95% CI p- Value
No. of Medications @ follow-up -1.4 (0.5079, 2.4206) 0.0031
Mixed Linear Models—Between-group mean difference
Linear Variable—Number
Variable Estimated Mean Difference(Control—Case)
95% CI p- Value
No. of Medications @ follow-up -1.4 (0.5079, 2.4206) 0.0031
Mixed Linear Models—Between-group mean difference
Linear Variable—Number
Average number of extra medications taken by Controls
Results—UnivariateVariable Comment
Results—UnivariateVariable Comment
Demographic RaceAgeGender
InsignificantMatchedMatched
Results—UnivariateVariable Comment
Demographic RaceAgeGender
InsignificantMatchedMatched
Anthropometric BMI Matched
Results—UnivariateVariable Comment
Demographic RaceAgeGender
InsignificantMatchedMatched
Anthropometric BMI Matched
Social Work StatusSmoking Status
InsignificantInsignificant
Results—UnivariateVariable Comment
Demographic RaceAgeGender
InsignificantMatchedMatched
Anthropometric BMI Matched
Social Work StatusSmoking Status
InsignificantInsignificant
Compliance Total Number of Follow-up VisitsDietary Compliance at Follow-upExercise Compliance at Follow-up
InsignificantSignificantInsignificant
Results—UnivariateVariable Comment
Demographic RaceAgeGender
InsignificantMatchedMatched
Anthropometric BMI Matched
Social Work StatusSmoking Status
InsignificantInsignificant
Compliance Total Number of Follow-up VisitsDietary Compliance at Follow-upExercise Compliance at Follow-up
InsignificantSignificantInsignificant
Disease Characteristics
Duration of ObesityFamily H/O Obesity
InsignificantInsignificant
Results—UnivariateVariables Comment
Results—UnivariateVariables Comment
Co-morbidities No. of Co-morbiditiesHepatic SteatosisDM
InsignificantInsignificantInsignificant
Results—UnivariateVariables Comment
Co-morbidities No. of Co-morbiditiesHepatic SteatosisDM
InsignificantInsignificantInsignificant
DyslipidemiaOn Anti-dyslipidemic Medications @ Baseline @Follow-up
Insignificant
InsignificantInsignificant
Results—UnivariateVariables Comment
Co-morbidities No. of Co-morbiditiesHepatic SteatosisDM
InsignificantInsignificantInsignificant
DyslipidemiaOn Anti-dyslipidemic Medications @ Baseline @Follow-up
Insignificant
InsignificantInsignificant
HTN On Anti-HTN Medications @ Baseline @Follow-up
Insignificant
SignificantInsignificant
Results—UnivariateVariables Comment
Co-morbidities No. of Co-morbiditiesHepatic SteatosisDM
InsignificantInsignificantInsignificant
DyslipidemiaOn Anti-dyslipidemic Medications @ Baseline @Follow-up
Insignificant
InsignificantInsignificant
HTN On Anti-HTN Medications @ Baseline @Follow-up
Insignificant
SignificantInsignificant
Prescription Medications @ Baseline @Follow-up
InsignificantSignificant
Results—UnivariateVariable Comment
Results—UnivariateVariable Comment
Related Diseases H/O DepressionH/O Thyroid dysfunctionH/O Major Surgeries
InsignificantInsignificantInsignificant
Results—UnivariateVariable Comment
Related Diseases H/O DepressionH/O Thyroid dysfunctionH/O Major Surgeries
InsignificantInsignificantInsignificant
Peri-operative Cholecystectomy done at ORPost-op LeakPost-op PEReturn to OR in 30 days
InsignificantInsignificantInsignificantInsignificant
Variable
Compliance Dietary Compliance at Follow-up Significant
Co-morbidities Prescriptions Medications at Follow-up Significant
Results—Multivariate
ConclusionAfter negating effects of Age, Gender and BMI:
Dietary non-compliance (reported by patients) predisposes to SWL.
ConclusionAfter negating effects of Age, Gender and BMI:
Dietary non-compliance (reported by patients) predisposes to SWL.
This should be stressed to patients before and after gastric bypass surgery.
ConclusionAfter negating effects of Age, Gender and BMI:
Dietary non-compliance (reported by patients) predisposes to SWL.
This should be stressed to patients before and after gastric bypass surgery.
“Self-reported loss of control over eating was related to weight regain after Gastric Bypass surgery and may be an important target for clinical intervention” (Kalarchian, Obes Surg 2002 Apr;12(2):270-5).
ConclusionAfter negating effects of Age, Gender and BMI:
Dietary non-compliance (reported by patients) predisposes to SWL.
This should be stressed to patients before and after gastric bypass surgery.
“Self-reported loss of control over eating was related to weight regain after Gastric Bypass surgery and may be an important target for clinical intervention” (Kalarchian, Obes Surg 2002 Apr;12(2):270-5).
Gradual enlargement of the gastric pouch.
Dietary and Exercise recommendation after Gastric BypassDiet:
1200-1400 Cal per day.60-80 g protein per day.4-5 small meals (especially breakfast).32 oz water per day.
Exercise:Walking 30 min/day, five to seven days per week.
Roux en Y Gastric By-pass
ConclusionAnti-HTN at baseline:
Probably a direct effect of a more serious disease and hence more SWL.
ConclusionAnti-HTN at baseline:
Probably a direct effect of a more serious disease and hence more SWL.
Prescription medications at follow-up:An indirect clue that patients who (were non-compliant and)
did not loose enough weight continued to need more medications.
Bigger and more powerful studies could potentially show other significant associations.
Conclusion
Bigger and more powerful studies could potentially show other significant associations.
Being a retrospective study, cause-effect relationship cannot be established—results show only associations.
Conclusion
Bigger and more powerful studies could potentially show other significant associations.
Being a retrospective study, cause-effect relationship cannot be established—results show only associations.
Data was partly patient reported/subjective- potential recall bias.
Conclusion
References1. WHO Fact sheet N°311, September 2006 2. Walter J. Pories; Who Would Have Thought It? ANNALS OF SURGERY
Vol. 222, No. 3, 339-352 3. Sjöström L; Lifestyle, Diabetes, and Cardiovascular Risk Factors 10 Years
after Bariatric Surgery. N Engl J Med 2004;3512683-93 4. Walter J. Pories; Bariatric Surgery: Risks and Rewards, J Clin Endocrinol
Metab 93: S89–S96, 2008) 5. Sjöström L; Effects of Bariatric Surgery on Mortality in Swedish Obese
Subjects. N Eng J Med 2007; 357: 741-52 6. Buchwald H; Yoav Avidor; Eugene Braunwald; et al. JAMA.
2004;292(14):1724-37 7. National Center for Health Statistics NHANES IV Report. Available at:
http://www.cdc.gov/nchs /product/pubs/pubd/hestats/obes/obese99 .htm2002. Accessed September 9, 2002.
References8. Halverson JK, Koehler RE. Gastric bypass: analysis of weight loss
and factors determining success. Surgery. 1981;90:446-455. 9. Brolin RE, Kenler HA, Gorman RC, Cody RP. The dilemma of
outcome assessment after operations for morbid obesity. Surgery. 1989;105:337-346.
10. Carbonell AM, Wolfe LG, Meador JG, et al. Does diabetes affect weight loss after gastric bypass? Surg Obes Relat Dis 2008;4:441-4.
11. Caruana et al; The Weight Loss Curve: A Nomogram for Monitoring the Response to Gastric Bypass
12. 12 Branson R; Impact of age, sex and body mass index on outcomes at four years after gastric banding: Obesity Surgery. 15(6):834-42, 2005 Jun-Jul
References13. Melton GB; Suboptimal weight loss after gastric bypass surgery:
correlation of demographics, comorbidities, and insurance status with outcomes: Journal of Gastrointestinal Surgery. 12(2):250-5, 2008 Feb
14. . Wittgrove AC, Clark GW. Laparoscopic gastric bypass, Rouxen-Y—500 patients: technique and results, with 3–60 month follow-up. Obes Surg 2000;10(3):233–239, Jun
15. Prachand VN, Davee RT, Alverdy JC. Duodenal switch provides superior weight loss in the super-obese (BMI > or =50 kg/m2) compared with gastric bypass. Ann Surg 2006;244(4):611–619,Oct
16. Choban PS, Flancbaum L. The effect of Roux limb lengths on outcome after Roux-en-Y gastric bypass: a prospective, randomized clinical trial. Obes Surg 2002;12(4):540–545, Aug.
17. Metropolitan Life Insurance Company